There are 2789 resources available
Polling 2 (led by chair)
Presenter: Nicolas Girard
Session: Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Nicolas Girard
Session: Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?
Resources:
Slides
Webcast
No
Presenter: Martin Reck
Session: Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?
Resources:
Slides
Webcast
Q&A
Presenter: Nicolas Girard
Session: Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?
Resources:
Slides
Webcast
Role of cancer drugs on WHO EML
Presenter: Lorenzo Moja
Session: WHO access to meaningful medicines
Resources:
Slides
Webcast
ESMO’s reimbursement model
Presenter: Panagiotis Kanavos
Session: WHO access to meaningful medicines
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Elisabeth de Vries
Session: WHO access to meaningful medicines
Resources:
Slides
Webcast
Staring through the window-of-opportunity: Phase 0 trials in oncology
Presenter: Emiliano Calvo
Session: YO Masterclass: Reshaping the future of clinical trials in oncology
Resources:
Slides
Webcast
Clinical trial designs fit for the future: How to address their integrity
Presenter: Nathan Cherny
Session: YO Masterclass: Reshaping the future of clinical trials in oncology
Resources:
Slides
Webcast
Discussion
Presenter: Teresa Amaral
Session: YO Masterclass: Reshaping the future of clinical trials in oncology
Resources:
Slides
Webcast